The board of directors of Dicot Pharma intends to resolve on a rights issue of approximately SEK 125 million
Uppsala, Sweden, June 30, 2024. The Board of Directors of Dicot Pharma AB ("Dicot" or the "Company") announces its intention to resolve on a rights issue of units consisting of shares and warrants (“Units”) equivalent to approximately SEK 125 million before deductions for transaction costs (the "Rights Issue"). In addition, the Company can receive additional proceeds from the warrants issued as part of the Units. The Board of Directors intends to publish a notice to an extraordinary general meeting (the "EGM") planned to be held on August 1, 2024, to authorize the Board of Directors to